China Sankei Observer: With the implementation of the national "14th Five-Year Plan", the pharmaceutical industry, as an important part of the national strategic industry, continues to promote industrial innovation and upgrading, which is of great significance for the construction of a healthy China and economic and social development. In the macro context of building a strong country in science and technology, Kanghong Pharmaceutical relies on its R&D heritage to deeply cultivate subdivided fields and promote the sustainable development of enterprises with innovation.
On December 1, Kanghong Pharmaceutical announced that the company received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration, and agreed to carry out a phase clinical trial to evaluate the safety, tolerability and pharmacokinetic properties of high-dose Conbercept Ophthalmic Injection**Diabetic Macular Edema (DME) with its flagship product, Conbercept Ophthalmic Injection.
Kanghong Pharmaceutical said that this is an exploration of the clinical application of high-dose Conbercept ophthalmic injection, which is expected to improve patients' medication compliance and reduce the medical burden.
It is understood that Conbercept ophthalmic injection is one of the main varieties of fundus disease in China, and has been approved for 4 indications.
Focus on areas of strength
In fact, after entering the fourth quarter, Kanghong Pharmaceutical is still exploring more R&D projects in terms of R&D in advantageous areas while continuing the market competitiveness of Conbercept ophthalmic injection. **Innovative chemical drug for depression - KH607 and ** innovative chemical drug for non-alcoholic steatohepatitis - KH629 have both received the notice of the US FDA agreeing to carry out clinical trials of new drugs, laying a good foundation for the next stage of development of the company.
When talking about the rapid growth of the number of innovative drugs in China, Kanghong Pharmaceutical told reporters that a new round of technological change is accelerating, which also increases the proportion of original achievements in China's pharmaceutical industry. Therefore, Kanghong needs to focus on continuous research and development in advantageous areas to ensure that it can keep up with the development speed of the new era of the pharmaceutical industry, and at the same time actively lay out new tracks such as gene ** and synthetic biology to promote the healthy development of the domestic innovative drug market.
Editor: Wang Yu.